ClinicalTrials.gg
RecruitingNCT06038396Updated Jan 29, 2025

A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

A Phase 1/2 interventional study of RC118 and Toripalimab in Advanced Solid Tumor, sponsored by RemeGen Co., Ltd.. Recruiting at 18 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-29.

Sponsored by RemeGen Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open, multi-center, dose escalation and expansion phase I/II study. The Phase I study will explore the tolerability and safety of RC118 in combination with Toripalimab for the treatment of patients with Claudin 18.2-positive, locally advanced unresectable or metastatic malignant solid tumors, and to establish the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); The Phase II study will evaluate the efficacy and safety of RC118 in combination with Toripalimab or RC148 in patients with locally advanced or metastatic Gastric cancer/Gastro-esophageal junction cancer.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

RemeGen Co., Ltd. is the lead sponsor of 83 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able to participate in the study voluntarily and willing to provide written .
  2. male or female 18 ≤ age ≤ 75 years old.
  3. Must have an (ECOG) Performance Status of 0 or 1.
  4. The expected survival ≥12 weeks.
  5. Enrollment of subjects with locally advanced or gastric adenocarcinoma/adenocarcinoma of the gastroesophageal junction who have a confirmed diagnosis and have failed standard therapy.
  6. Subjects who received ≤2 prior systemic therapies.
  7. Subjects agree to provide tumor tissue specimens for Claudin 18.2 and expression levels during the screening period. Samples should have moderate to high expression of Claudin 18.2 by membrane staining.
  8. According to the v1.1, there is at least one measurable target lesion.
  9. Sufficient heart, bone marrow, liver and kidney functions.
  10. Fertile male or female subjects must agree to take effective measures during the study period and for 6 months after the end of the last dose, such as double-barrier contraceptive methods(eg. condoms), oral or injectable contraceptives, intrauterine.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant women, breastfeeding women or women with a positive blood pregnancy test result during the screening period (non-fertile women do not need to undergo a pregnancy test, such as women with a previous hysterectomy and/or bilateral oophorectomy or amenorrhea ≥12 months).
  2. Subjects with active (HBsAg positivity and HBV DNA titre higher than the normal upper limit), active (HCVAb positivity and HCV RNA titre higher than the normal upper limit), and positive antibody (HIV-Ab) results during the screening period.
  3. Subjects with a history of other acquired or congenital immunodeficiency diseases, or who have undergone organ or bone marrow transplantation.
  4. Subjects who have previously received monoclonal antibody, double antibody targeting drugs, ADC, CAR-T and other therapeutic drugs targeting Claudin 18.2 or other ADCs with MMAE payload; or have participated in clinical trials and received drugs within 4 weeks before the first dose.
  5. Have vaccinated within 4 weeks prior to the first dose or plan to receive any during the study.
  6. Subjects are atallergic to the ingredients or of the experimental drug.
  7. Subjects who have received anti-tumor therapy (chemotherapy, radiotherapy, immunotherapy, or targeted therapy) within 4 weeks or less than 5 half-lives of the experimental drug prior to the start of the first dose; or who have received anti-tumor therapy with traditional Chinese medicine or immunomodulators within 2 weeks prior to the start of the first dose.
  8. The toxicity of previous anti-tumor therapy has not returned to the level 0 or 1 as defined by v5.0 (except for alopecia, pigmentation and other long-term toxicity ≤2 that cannot be recovered which was defined by investigators).
  9. The clinical symptoms of pleural effusion, abdominal effusion, or pericardial effusion that requires drainage.
  10. Active infection within 2 weeks prior to the first dose that requires systemic anti-inflammatory therapy.
  11. Complicating other diseases that seriously endanger the safety of the subjects or affect the completion of the study, such as peptic ulcer, intestinal obstruction, intestinal paralysis, interstitial pneumonia, pulmonary fibrosis, renal failure and uncontrolled diabetes (Fasting blood glucose > 8.5 mmol/L, ≥7.5%).
  12. The tumor lesion has a bleeding tendency or has received blood transfusion treatment within 4 weeks prior to the first dose.
  13. During the screening period, >450 ms(male), QTc interval >470ms(female); previous family or personal history of long/short QT interval syndrome; A history of ventricular arrhythmia deemed by the investigator, or currently receiving antiarrhythmic medication, or implantation of arrhythmia defibrillation device.
  14. Previous myocardial infarction (within 6 months prior to the first dose), severe or unstable angina, coronary or peripheral artery bypass grafting, heart failure grade 3\~4 defined by (NYHA) and uncontrolled hypertension.
  15. Experienced an arterial/venous thromboembolic event within 6 months prior to the study.
  16. Active disease that requires systemic treatment within 2 years prior to the study. Patients with vitiligo, psoriasis, alopecia or Grave's disease that not requires systemic treatment, hypothyroidism that only requires thyroid hormone replacement therapy, and type 1 diabetes only requires insulin replacement therapy may be included in the study.
  17. Subjects with and/or carcinomatous meningitis who have previously received related treatment may be considered for inclusion if their disease has been stable for at least 3 months, no imaging evidence of disease progression has been observed within 4 weeks prior to the first dose, all neurological symptoms have returned to baseline, and radiation, surgery, or therapy has been discontinued at least 28 days prior to the first dose; cancerous meningitis should be excluded regardless of whether it is clinically stable.
  18. Other malignant tumor within 5 years prior to the signature of .
  19. Major surgery or interventional therapy was performed within 4 weeks prior to the first dose and did not fully recovered (except tumor and puncture).
  20. For Phase II subjects:

    • Received an (anti-PD-1/PD-L1/CTLA-4 antibody) or other immune checkpoint inhibitor therapy within 28 days prior to the first treatment with the test drug;
    • Prior concurrent receipt of antitumor agents targeting VEGF/VEGFR and PD-1/PD-L1;
    • Experienced permanent discontinuation of immunotherapy due to toxicity of immune checkpoint inhibitor therapy prior to receiving administration of study drug;
    • Currently receiving anticoagulant medications (except for subjects on prophylactic doses of heparin).
  21. A history of uncontrollable mental illness or subjects currently experiencing such conditions.
  22. Subjects with poor compliance who are expected to be unable to complete the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Part A-RC118 plus Toripalimab

    Participants receive RC118- ADC(dose A or dose B) Q2W and Toripalimab (fixed dose) Q3W

    Drug: RC118 · Drug: Toripalimab

  • Experimental
    Part B-RC118 plus Toripalimab / RC148

    Referring to the results of the Part A, an extension cohort using RC118 plus Toripalimab /RC148 will be established.

    Drug: RC118 · Drug: Toripalimab · Drug: RC148

Interventions

  • DrugRC118

    Dose A or dose B, Q2W

    Also known as: RC118 for injection

  • Fixed dose, Q3W

    Also known as: Toripalimab injection, JS001

  • DrugRC148

    Fixed dose, Q3W Other Names: RC148 injection

06

What researchers measure

Primary outcomes

  1. Phase1: Dose limiting toxicity (DLT)

    Toxicity occurs within the DLT evaluation window (1-21 days after the first dose) that the investigator or sponsor believes to be reasonably associated with RC118 or Toripalimab according to NCI-CTCAE v5.0.

    Time frame: The first 3 weeks (21 days) after the start of dosing at each dose level

  2. Phase1/2: Adverse events (AEs)

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and clinically significant abnormal laboratory results.

    Time frame: [Time Frame: 15 months]

  3. Phase1: Maximum tolerated dose(MTD)

    Maximum tolerated dose(MTD)

    Time frame: up to 12 months

  4. Phase1: Recommended Phase 2 Dose (RP2D)

    Recommended Phase 2 Dose (RP2D)

    Time frame: up to 12 months

  5. Phase 2: Objective response rate (ORR)

    The proportion of patients whose BOR is a confirmed CR or PR. Tumor response will be evaluated using RECIST v.1.1.

    Time frame: 15 months

Secondary outcomes

  1. Disease Control Rate (DCR)

    The percentage of patients who have achieved an objective response of confirmed CR ,PR or SD as assessed by the investigator per RECIST v1.1)

    Time frame: 15 months

  2. Progression-free survival (PFS)

    The time from first dose to disease progression(as assessed by investigators according to RECIST v1.1 criteria) (as measured by the first event).

    Time frame: 15 months

  3. Duration of Remission (DOR)

    The time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death.

    Time frame: 15 months

  4. Overall survival (OS)

    The time from the date of the first dose of study treatment to the date of death.

    Time frame: 15 months

  5. Phase 1: Objective response rate (ORR)

    The proportion of patients whose BOR is a confirmed CR or PR. Tumor response will be evaluated using RECIST v.1.1.

    Time frame: 15 months

  6. Peak and valley concentrations of RC118, total antibody, and free MMAE

    Peak and valley concentrations of C118 binding antibody, total antibody, and free MMAE were observed.

    Time frame: 15 months

  7. RC118 immunogenicity: The incidence, time of onset, duration of patients with anti-drug-antibody (ADA)

    RC118 immunogenicity: The incidence, time of onset, duration of patients with anti-drug-antibody (ADA)

    Time frame: 15 months

07

Study locations

18 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Feb 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2023
First posted
Sep 14, 2023
StartActual
Aug 3, 2023
Primary completionEst.
Feb 28, 2026
CompletionEst.
Aug 31, 2026
Last update
Jan 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06038396
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Sep 14, 2023
Start date
Aug 3, 2023
Primary completion
Feb 28, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Jan 29, 2025

Study contacts

Xiaohong Su
Contact
na.su@remegen.com
+8610-65018841
Tianshu Liu, ph.D
Contact
liu.tianshu@zs-hospital.sh.cn
+86-21-31587871
Tianshu Liu, ph.D
principal investigator · Shanghai Zhongshan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ciletatug vedotin · Toripalimab

Start the discussion